News

Life Sciences

Loxo Oncology Awaiting FDA's Decision Monday on Lead Cancer Therapeutic

Edward Kim | Equities.com |

Monday, Nov. 26th, is the PDUFA date for larotrectinib, Loxo's candidate to treat TRK fusion cancers (Image: Loxo Oncology)


Novimmune and Sobi Get FDA Approval for First Ever Primary HLH Therapy

Edward Kim | Equities.com |

First FDA-approved treatment for primary haemophagocytic lymphohistiocytosis (HLH). (Image: Novimmune)


GlycoMimetics Doses First Patient in Phase 3 Advanced Acute Myeloid Leukemia Study

Edward Kim | Equities.com |

Global study to evaluate uproleselan in 380 patients with Relapsed/Refractory AML (Image: GlycoMimetics)


Cadent Therapeutics Raises $40 Million Series B for Movement and Cognitive Disorders

Edward Kim | Equities.com |

Financing supports near-term initiation of Phase 2 trials in essential tremor and spinocerebellar ataxia (Image: Cadent Therapeutics).


Attenua Treats First Patient in Phase 2 Study for Chronic Cough

Edward Kim | Equities.com |

Phase 2 trial for non-opioid chronic cough therapy initiated just 6 months after Series A funding (Image: Attenua)


Gene-Edited Food Is Coming, but Will Shoppers Buy?

Associated Press | Equities.com |

A new generation of biotech foods is getting close to the grocery aisles.


Genentech Gets FDA Priority Review Designation for Combination Treatment of Triple-Negative Breast Cancer

Edward Kim | Equities.com |

Tecentriq-Abraxane combination would be the first cancer immunotherapy for PD-L1-positive, metastatic triple-negative breast cancer (Image: Mayo Clinic)


5 Things to Know About Moderna's Proposed $500 Million IPO

Edward Kim | Equities.com |

The proposed deal for this biotechnology unicorn would be the largest US IPO in the industry (Image: Moderna)


Alpine Immune Sciences Shows Positive Preclinical Data for Cancer Immunotherapy

Edward Kim | Equities.com |

ALPN-202 combines dual checkpoint blockade action with T-cell costimulation


Mirum Pharmaceuticals Launches with $120 Million Series A and Phase 3-Ready Candidate for Rare Liver Diseases

Edward Kim | Equities.com |

Financing led by NEA. Drug candidate licensed from Shire for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).


Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     

INTERVIEW: CEO Dr. Martin Eaton - Heads Up Checkup

Equities.com Host & Contributor Silvia Davi interviewing CEO of Heads Up Checkup, Dr. Martin Eaton.